Advanced

Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry.

Abrahamsson, Anna; Dahle, Nina and Jerkeman, Mats LU (2011) In Leukemia & lymphoma 52(10). p.1929-1935
Abstract
Abstract In recent years, more intensive chemotherapy regimens for mantle cell lymphoma (MCL) have been associated with prolongation of survival. In this study, our aim was to investigate prognostic factors and evaluate improvement in survival in MCL on a population level. The cohort included all patients diagnosed with MCL from 1 January 2000 to 31 March 2010 in the Swedish Lymphoma Registry. At total of 785 patients with MCL were identified. Age, performance status, and B-symptoms were significant prognostic factors for overall survival (OS) in multivariate analysis. In addition, OS was markedly improved (hazard ratio 0.8, 95% confidence interval 0.7-0.9) for patients diagnosed during the latest time period, 2006-2010, also when... (More)
Abstract In recent years, more intensive chemotherapy regimens for mantle cell lymphoma (MCL) have been associated with prolongation of survival. In this study, our aim was to investigate prognostic factors and evaluate improvement in survival in MCL on a population level. The cohort included all patients diagnosed with MCL from 1 January 2000 to 31 March 2010 in the Swedish Lymphoma Registry. At total of 785 patients with MCL were identified. Age, performance status, and B-symptoms were significant prognostic factors for overall survival (OS) in multivariate analysis. In addition, OS was markedly improved (hazard ratio 0.8, 95% confidence interval 0.7-0.9) for patients diagnosed during the latest time period, 2006-2010, also when corrected for prognostic factors as above. Estimated OS at 3 years was 62%, compared to 47% for patients diagnosed earlier (p < 0.01). The reasons for this dramatic improvement in OS are not yet clear, but may be due to the introduction of specific and more potent therapeutic regimens. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Leukemia & lymphoma
volume
52
issue
10
pages
1929 - 1935
publisher
Taylor & Francis
external identifiers
  • wos:000295176800018
  • pmid:21702648
  • scopus:80053189765
ISSN
1029-2403
DOI
10.3109/10428194.2011.587560
language
English
LU publication?
yes
id
492158c5-1db9-4930-b1b6-0a589ff33903 (old id 2007771)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/21702648?dopt=Abstract
date added to LUP
2011-07-06 11:08:45
date last changed
2017-11-12 03:42:16
@article{492158c5-1db9-4930-b1b6-0a589ff33903,
  abstract     = {Abstract In recent years, more intensive chemotherapy regimens for mantle cell lymphoma (MCL) have been associated with prolongation of survival. In this study, our aim was to investigate prognostic factors and evaluate improvement in survival in MCL on a population level. The cohort included all patients diagnosed with MCL from 1 January 2000 to 31 March 2010 in the Swedish Lymphoma Registry. At total of 785 patients with MCL were identified. Age, performance status, and B-symptoms were significant prognostic factors for overall survival (OS) in multivariate analysis. In addition, OS was markedly improved (hazard ratio 0.8, 95% confidence interval 0.7-0.9) for patients diagnosed during the latest time period, 2006-2010, also when corrected for prognostic factors as above. Estimated OS at 3 years was 62%, compared to 47% for patients diagnosed earlier (p &lt; 0.01). The reasons for this dramatic improvement in OS are not yet clear, but may be due to the introduction of specific and more potent therapeutic regimens.},
  author       = {Abrahamsson, Anna and Dahle, Nina and Jerkeman, Mats},
  issn         = {1029-2403},
  language     = {eng},
  number       = {10},
  pages        = {1929--1935},
  publisher    = {Taylor & Francis},
  series       = {Leukemia & lymphoma},
  title        = {Marked improvement of overall survival in mantle cell lymphoma: a population based study from the Swedish Lymphoma Registry.},
  url          = {http://dx.doi.org/10.3109/10428194.2011.587560},
  volume       = {52},
  year         = {2011},
}